Literature DB >> 36190854

Local-Regional Treatment of Hepatocellular Carcinoma: A Primer for Radiologists.

Natally Horvat1, Ana I de Oliveira1, Brunna Clemente de Oliveira1, Jose A B Araujo-Filho1, Maria El Homsi1, Ahmed Elsakka1, Raazi Bajwa1, Guilherme L P Martins1, Khaled M Elsayes1, Marcos R Menezes1.   

Abstract

The treatment planning for patients with hepatocellular carcinoma (HCC) relies predominantly on tumor burden, clinical performance, and liver function test results. Curative treatments such as resection, liver transplantation, and ablative therapies of small lesions should be considered for all patients with HCC. However, many patients are ineligible for these treatments owing to advanced disease stage and comorbidities. Despite efforts to increase screening, early-stage HCC remains difficult to diagnose, which decreases the possibility of curative therapies. In this context, local-regional treatment of HCC is accepted as a form of curative therapy in selected patients with early-stage disease, as a therapeutic option in patients who are not eligible to undergo curative therapies, as a downstaging approach to decrease tumor size toward meeting the criteria for liver transplantation, and as a bridging therapy to avoid tumor growth while the patient is on the waiting list for liver transplantation. The authors review the indications, types, mechanism of action, and possible complications of local-regional treatment, as well as the expected postprocedural imaging features of HCC. Furthermore, they discuss the role of imaging in pre- and postprocedural settings, provide guidance on how to assess treatment response, and review the current limitations of imaging assessment. Finally, the authors summarize the potential future directions with imaging tools that may add value to contemporary practice at response assessment and imaging biomarkers for patient selection, treatment response, and prognosis. ©RSNA, 2022.

Entities:  

Mesh:

Year:  2022        PMID: 36190854      PMCID: PMC9539394          DOI: 10.1148/rg.220022

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   6.312


  76 in total

Review 1.  State-of-the-art in radiomics of hepatocellular carcinoma: a review of basic principles, applications, and limitations.

Authors:  Joao Manoel Miranda Magalhaes Santos; Brunna Clemente Oliveira; Jose de Arimateia Batista Araujo-Filho; Antonildes N Assuncao-Jr; Felipe Augusto de M Machado; Camila Carlos Tavares Rocha; Joao Vicente Horvat; Marcos Roberto Menezes; Natally Horvat
Journal:  Abdom Radiol (NY)       Date:  2020-02

Review 2.  Arterially directed therapies for hepatocellular carcinoma.

Authors:  Rajesh P Shah; Karen T Brown; Constantinos T Sofocleous
Journal:  AJR Am J Roentgenol       Date:  2011-10       Impact factor: 3.959

3.  Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Al B Benson; Michael I D'Angelica; Daniel E Abbott; Daniel A Anaya; Robert Anders; Chandrakanth Are; Melinda Bachini; Mitesh Borad; Daniel Brown; Adam Burgoyne; Prabhleen Chahal; Daniel T Chang; Jordan Cloyd; Anne M Covey; Evan S Glazer; Lipika Goyal; William G Hawkins; Renuka Iyer; Rojymon Jacob; R Kate Kelley; Robin Kim; Matthew Levine; Manisha Palta; James O Park; Steven Raman; Sanjay Reddy; Vaibhav Sahai; Tracey Schefter; Gagandeep Singh; Stacey Stein; Jean-Nicolas Vauthey; Alan P Venook; Adam Yopp; Nicole R McMillian; Cindy Hochstetler; Susan D Darlow
Journal:  J Natl Compr Canc Netw       Date:  2021-05-01       Impact factor: 11.908

Review 4.  Locoregional therapies for hepatocellular carcinoma and the new LI-RADS treatment response algorithm.

Authors:  Ania Kielar; Kathryn J Fowler; Sara Lewis; Vahid Yaghmai; Frank H Miller; Hooman Yarmohammadi; Charles Kim; Victoria Chernyak; Takeshi Yokoo; Jeffrey Meyer; Isabel Newton; Richard K Do
Journal:  Abdom Radiol (NY)       Date:  2018-01

Review 5.  MRI Assessment of Hepatocellular Carcinoma after Local-Regional Therapy: A Comprehensive Review.

Authors:  Mishal Mendiratta-Lala; William R Masch; Kimberly Shampain; Andrew Zhang; Alexandria S Jo; Sarah Moorman; Anum Aslam; Katherine E Maturen; Matthew S Davenport
Journal:  Radiol Imaging Cancer       Date:  2020-01-31

6.  The road less traveled: importance of the lesser branches of the celiac axis in liver embolotherapy.

Authors:  Aram J Lee; Antoinette S Gomes; David M Liu; Stephen T Kee; Christopher T Loh; Justin P McWilliams
Journal:  Radiographics       Date:  2012 Jul-Aug       Impact factor: 5.333

Review 7.  BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.

Authors:  Maria Reig; Alejandro Forner; Jordi Rimola; Joana Ferrer-Fàbrega; Marta Burrel; Ángeles Garcia-Criado; Robin K Kelley; Peter R Galle; Vincenzo Mazzaferro; Riad Salem; Bruno Sangro; Amit G Singal; Arndt Vogel; Josep Fuster; Carmen Ayuso; Jordi Bruix
Journal:  J Hepatol       Date:  2021-11-19       Impact factor: 30.083

8.  Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

Authors:  Riccardo Lencioni; Josep M Llovet; Guohong Han; Won Young Tak; Jiamei Yang; Alfredo Guglielmi; Seung Woon Paik; Maria Reig; Do Young Kim; Gar-Yang Chau; Angelo Luca; Luis Ruiz Del Arbol; Marie-Aude Leberre; Woody Niu; Kate Nicholson; Gerold Meinhardt; Jordi Bruix
Journal:  J Hepatol       Date:  2016-01-22       Impact factor: 25.083

9.  Magnetic resonance-guided laser-induced thermotherapy in patients with oligonodular hepatocellular carcinoma: long-term results over a 15-year period.

Authors:  Katrin Eichler; Stephan Zangos; Tatjana Gruber-Rouh; Thomas J Vogl; Martin G Mack
Journal:  J Clin Gastroenterol       Date:  2012-10       Impact factor: 3.062

10.  Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization.

Authors:  Jin-Kyu Kang; Mi-Sook Kim; Chul Koo Cho; Kwang Mo Yang; Hyung Jun Yoo; Jin Ho Kim; Sun Hyun Bae; Da Hoon Jung; Kum Bae Kim; Dong Han Lee; Chul Ju Han; Jin Kim; Su Cheol Park; Young Han Kim
Journal:  Cancer       Date:  2012-05-08       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.